The document discusses the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device that provides a tri-modal mechanism of action to lower intraocular pressure. Over 3,200 patients have been treated globally using the Hydrus Microstent. Clinical studies and a large global registry have shown the Hydrus Microstent to provide superior outcomes compared to other MIGS devices, with a 20% reduction in diurnal intraocular pressure and increased treatment response rates. The Hydrus Microstent expands treatment opportunities for both standalone glaucoma procedures and combined cataract/glaucoma surgeries.

1. The Hydrus™ Microstent
Expanding MIGS
Treatment Opportunities

2. • $132 MM raised to date
from multinational VC
base
• Over 3,200 patients
treated globally (21
countries, 80 surgeons)
• Studied in multiple level-
one clinical studies and
a large global registry
Global Hydrus Procedures
Ivantis Overview
Investigational Device Only in US 2
MISSION
Expand patient treatment and improve outcomes
through an innovative MIGS solution

3. SAFETY
20%
Investigational Device Only in US
MIGS Treatment Paradigm
1) “The Emergence of the 5-Tool Glaucoma Surgeon”, AGS 2017
MILD / MODERATE LATE MODERATE / ADVANCED
80%
5M US Diagnosed Glaucoma Patients
CONVENTIONAL OUTFLOW
Schlemm’s Canal
iStent
BYPASS DEVICES
Suprachoroidal/ Subjunctival
InnFocusCyPassXEN
“Canal Will Be First.”
- Thomas Samuelson, MD1
Comprehensive Ophthalmologist Glaucoma Specialist
~$1.6B3
$300M2
$240M2
$225M2
2) Bypass device valuations reflect upfront acquisition price and do not include milestone payments
3) GKOS Public Market Valuation as of May 1, 2017

4. Hydrus: Next Generation Canal-based MIGS
Investigational Device Only in US
Tri-Modal Mechanism of Action
DILATION COVERAGE
90º
Optimal
Outflow
BYPASS

5. Reliable Access to Multiple Collector Channels
Leads to Consistent Results
Investigational Device Only in US 5

6. STANDALONE
(glaucoma only)
COMBINED
(phaco/glaucoma)
Hydrus Expands Treatment Opportunities
Investigational Device Only in US
Hydrus Addresses Treatment Needs in
Both Markets

7. T R E AT M E N T R E S P O N S E
80%
46%
0%
20%
40%
60%
80%
100%
24 Months
20% Drop in Washed Out
Diurnal IOP
Hydrus
Control
Analysis conducted on intention-to-treat basis
(N=50) (N=50)
(N=50) (N=50)
Superior Outcomes in Combined Procedure
Investigational Device Only in US 7
= 34%
P = 0.0008
Hydrus increases
response by 74%
558 Subject HORIZON
U.S. Pivotal 2 year data
will be presented at AAO
2017

8. Value Proposition for Comprehensive
Ophthalmologist and Referring Optometrist
Investigational Device Only in US
• “One and done” and
reproducible approach
• Allows for access to
multiple collector
channels every time
RELIABLE
PLACEMENT
HIGHEST PATIENT
SATISFACTION
• Surgeon “promise” is
optimal refractive
outcome with best chance
to be safely off
medications

9. STANDALONE
(glaucoma only)
COMBINED
(phaco/glaucoma)
Hydrus Expands Treatment Opportunities
Investigational Device Only in US
Hydrus Addresses Treatment Needs in
Both Markets

10. Investigational Device Only in US
Standalone: The Next Frontier in MIGS
MILD MODERATE ADVANCED
COMPARE
Landmark Comparative Effectiveness Trial
• First level-one MIGS trial comparing 2 MIGS
devices in prospective, controlled conditions
• Mild to moderate glaucoma
• 152 eyes, 11 centers, 8 countries
• Expert users (performed at least 20 of each
procedure prior to trial)
• Full 1 year results collected and now collecting
2 year results
• Trial announced last week
• Advanced (Refractory Glaucoma)
• 60 patients, 15 centers, US and ex-US, with
12 month follow-up
• First patient projected within 30 days
• First MIGS device to have 2 FDA pivotal trials on
opposite ends of glaucoma disease spectrum
SUMMIT
Refractory Glaucoma IDE Trial
• Evaluation of “real-world” Hydrus Microstent utilization, safety, and
effectiveness
• Full spectrum of glaucoma, from mild-moderate to refractory
• 28% of procedures stand-alone
• > 2,000 eyes at 45 centers in 14 countries
SPECTRUM
Global Multi-center Registry

11. • Micro pressure sensor housed within
Hydrus
• Wireless link to a smart phone
Investigational Device Only in US 11
Unique Design Allows for Platform Technology
24 Hour IOP Monitor
ADVANCED
DISEASE
• Hydrus platform to provide long-term
drug delivery
• Delivery of therapeutic agent that works
with Hydrus to enhance both MOAs
Bioresorbable Drug Delivery
Expanded Indications
• Potential applications in other markets
such as angle closure glaucoma and
normal tension glaucoma
NEW
MARKETS
DIAGNOSTIC